The science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway
|
|
- Kristian Percival Rich
- 6 years ago
- Views:
Transcription
1 The science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway
2 Speaker credentials Roy H. Larsen, PhD >25 years of experience in research on targeted radionuclide therapy Main founder of Algeta and inventor of Xofigo, and approved radionuclide therapy targeting bone metastases in cancer patients (sold by Bayer) Main inventor of >15 families of patents/patent applications Author of >50 peer-reviewed papers Chairman of the Board of Directors of Nordic Nanovector from , and is now a member of the Board of Directors of Nordic Nanovector 2
3 Antibody-radionuclide conjugates 3
4 Targeting cancer cells Cancer cells present various proteins on their cell surfaces, which can be exploited therapeutically using targeted therapies Traditional monoclonal antibodies such as rituximab (MabThera ) target cell-surface proteins such as CD20 that are present on the surface of lymphoma cells These therapies work by recruiting the immune system to kill the cancer cells Additionally, other molecules can be linked to these antibodies in order to provide further clinical benefit or an alternative anticancer mechanism 4
5 Antibody-radionuclide conjugates Immunoconjugates are antibodies that are joined to a second molecule via a linker This second molecule is usually a label, cytotoxic molecule, or radionuclide Antibody-drug conjugates (ADCs) Antibody-radionuclide conjugates (ARCs) An antibody joined to a cytotoxic molecule; these are known together as an immunotoxin Examples of ADCs include: Adcetris Kadcyla An antibody joined to a radionuclide; treatment is often referred to as radioimmunotherapy Examples of ARCs include: Zevalin Bexxar Source: Nordic Nanovector prospectus 5
6 Antibody-radionuclide conjugates: mechanism of action ARCs provide a way to selectively deliver a radioactive payload to cancer cells The binding of the antibody to the cellsurface protein brings the radionuclide in close proximity to the cancer cell The emitted radiation kills the target cell along with surrounding cancer cells ARC: antibody-radionuclide conjugate 6
7 Radionuclides are an accepted part of cancer treatment Radium was investigated as a targeted treatment for bone disease due to its chemical similarity with calcium Radium is readily available for production and has a 11.4 day half-life that allows easy shipping to end users μm Radium selectively concentrates in bone lesions Harrison MR et al. Cancer Manage Res. 2013;5:
8 Xofigo (Radium-223) has seen clinical and commercial success 3.6 month extended survival led to priority FDA and EMA review, followed by approval in 2013 Xofigo was in the top 10 drugs of 2013, with projected 2018 sales of $829 million EMA: European Medicines Agency; FDA: Food and Drug Administration 8
9 Betalutin 9
10 Intellectual property (IP) protection: Betalutin Betalutin is protected by the strongest form of IP protection Composition of Matter I. Patents already granted/issued in the USA, Europe, China and Japan; patent applications are still being processed in other geographies II. The patent protects Betalutin as well as radioimmunotherapies based on other radionuclides and chelators attached to the HH1 antibodies Nordic Nanovector also has patent applications on specific versions of humanized and chimeric versions of the HH1 antibody The third layer of IP protection for Betalutin is a Use Patent application regarding the upregulation of tumor antigens by treatment with Betalutin and subsequent possible enhanced therapeutic effect of immunotherapies like rituximab 10
11 Betalutin : a new radioimmunoconjugate against CD37 Betalutin is an ARC designed to target the CD37 protein on the surface on NHL cells HH1 antibody that targets CD37 + Lutetium-177 (Lu-177) a beta-particle emitting radionuclide with a 6.7 day half-life + DOTA linker 177 Lu ARC: antibody-radionuclide conjugate; NHL: non-hodgkin lymphoma 11
12 CD37 is a validated target for non-hodgkin lymphoma CD37 is one of the many potential antibody targets for cancers such as NHL 1 CD37 is well expressed in NHL 1 CD37 is expressed on the same cell subset as CD20, mainly mature B cells and B-cell malignancies 2 3 NHL, non-hodgkin lymphoma 1. Flinn IW. Blood 2011; 118: ; 2. Palomba ML, Younes A. Blood 2013; 122: ; 3. Figure redrawn from Flinn IW. Blood 2011; 118: Blood: Journal of the American Society of Hematology by American Society ofhematology; Reproduced with permission of AMERICAN SOCIETY OF HEMATOLOGY (ASH) 12
13 Pre-clinical and clinical data supporting CD37 targeting Pre-clinical In vitro tests with the antibody construct (TRU-016), suggest that CD37-targeted proteins induce cell death by a different mechanism of action vs rituximab 1 Mice inoculated with a CD37-targeted ADC had a superior tumor-free survival time than those given an unconjugated antibody or the anti-cd20 antibody rituximab 2 Survival of mice treated with Betalutin was significantly higher than those treated with rituximab 3 Clinical Treatment of refractory NHL patients with the 131 I-MB-1 anti-cd37 antibody 4 4 patients achieved complete tumor remission 1 patient treated with an anti-cd20 achieved partial response Radioimmunotherapy with 131 I-MB-1 anti-cd37 antibody 5 6 of 10 patients achieved tumor response Much lower doses of 131 I than in the previous study ADC: antibody-drug conjugate; NHL: non-hodgkin lymphoma; TRU-016: otlertuzumab 1. Zhao X et al. Blood 2007; 110: ; 2. Deckert J et al. Blood 2013; 122: ; 3. Dahle J et al. Anticancer Res 2013; 33: 85 96; 4. Press OW et al. J Clin Oncol 1989; 7: ; 5. Kaminski MS et al. J Clin Oncol 1992; 10:
14 Lutetium-177 is well suited for non-hodgkin lymphoma treatment Properties of Lu-177 T ½ (half-life) 6.7 days Mean b-energy 0.13 MeV Mean range in tissue 0.67 mm ICRP radiotoxicity 3 g-yield 17% g-energies 113 and 208 kev Half-life long enough to ensure that tumor mass is irradiated Mean range of radiation treats bulky tumors while limiting damage to health tissue Sufficient gamma component to obtain imaging, but low enough to allow safe treatment in an outpatient setting Imaging possible? Yes ICRP: International Commission on Radiological Protection; kev: kiloelectronvolt; MeV: megaelectronvolt 14
15 Betalutin : summary Different targeting antibody focusing on a different antigen vs rituximab (CD37 vs CD20) Greater anticipated effect in patients not responding to rituximab (CD20) Different β-emitting radionuclide with better therapeutic and safety properties Longer half-life (6.7 days) than Y-90 Lower β-energy (mean range 0.67 mm) than Y-90 Long intracellular half-life Low yield of photons (17%), with suitable energy for imaging Ready-to-use formulation Y-90: Zevalin 15
16 Future opportunities with Betalutin 16
17 Nordic Nanovector s pipeline Indication FL, 3rd line FL, 2nd line DLBCL, ineligible for ASCT DLBCL, conditioning Other NHL FL, 1st line Leukemia Multiple myeloma Product candidate Discovery Preclinical Phase 1 Phase 2 Phase 3 Betalutin Betalutin + CD20 Betalutin Betalutin Betalutin + CD Lu-chHH1 ARC 177 Lu-chHH1 ARC Affilutin* *Collaboration with Affibody ARC: antibody -radionuclide conjugate; ASCT: autologous stem cell transplant; chhh1: chimeric HH1 antibody; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; NHL: non-hodgkin lymphoma 17
18 Betalutin treatment may improve rituximab efficiency Biodistribution of rituximab in the blood and tumor of mice improved after treatment with Betalutin In a preclinical mouse model of MCL, treatment with the combination of Betalutin plus rituximab appears to be associated with increased survival, compared with rituximab alone MCL: mantle cell lymphoma 18
19 Pre-clinical results: CD37 (HH1) vs CD20 (rituximab) Internalized antibody (fg/cell) HH1 tetulomab rituximab Antibodies bound to CD37 (HH1) are internalized Antibodies bound to CD20 (rituximab) are not internalized Time after start of incubation (min) Betalutin is designed for internalization and high retention in cancer cells, which causes greater cancer cell death 19
20 Overview of chhh1-arc chhh1-arc is based on a chimeric antibody linked to the radioactive Lu-177 nuclide Target: CD37 chhh1-arc allows: Repeated injections over time making it suitable for first-line use Fractionated dosing making it suitable for chronic lymphocytic leukemia Potential for synergistic effect when combined with anti-cd20 antibody leading to an efficacy profile that can compete with first-line regimens across multiple hematologic cancers Status: Preliminary studies have shown relevant uptake of chhh1 ARC in normal organs and tumor xenografts, and strong cytotoxicity of chhh1 ARC in vitro In vivo efficacy/toxicity studies are ongoing ARC: antibody-radionuclide conjugate; chhh1: chimeric HH1 antibody 20
21 Overview of Affilutin Affibody-radionuclide conjugate based on an affibody molecule and a Lu-177 radioactive nuclide Development in collaboration with Affibody AB and funding from the Eurostars programme Target undisclosed surface antigen Indication multiple myeloma Status: Initial affibody molecules (hits) have been identified and characterized in cells and the relevant tumor models Affinity maturation of lead molecules is ongoing Affibody molecule Lu-177 Affilutin 21
22 Summary 22
23 Betalutin : a first-in-class antibody-radionuclide conjugate Tumor-seeking monoclonal anti-cd37 antibody + conjugated radionuclide (Lu-177) Effective therapeutic payload and multi-cell kill approach Specifically designed for the treatment of B-cell tumors 23
Introducing a First-in-Class treatment for Non-Hodgkin Lymphoma Carnegie Healthcare Conference, March 17, 2016 Marco Renoldi, Chief Business Officer
Introducing a First-in-Class treatment for Non-Hodgkin Lymphoma Carnegie Healthcare Conference, March 17, 2016 Marco Renoldi, Chief Business Officer Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo,
More informationIntroducing a First-in-Class treatment for Non-Hodgkin Lymphoma BioEquity Europe 2016, Copenhagen May 11, 2016 Luigi Costa, Chief Executive Officer
Introducing a First-in-Class treatment for Non-Hodgkin Lymphoma BioEquity Europe 2016, Copenhagen May 11, 2016 Luigi Costa, Chief Executive Officer Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo,
More informationDEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS
DEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS DEUTSCHE BANK 42ND ANNUAL HEALTH CARE CONFERENCE MAY 4, 2017 LUIGI COSTA, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com
More informationDeveloping First-in-Class Treatments in Haematologic Cancers DNB Healthcare Conference, Thursday December 15 th, 2016
Developing First-in-Class Treatments in Haematologic Cancers DNB Healthcare Conference, Thursday December 15 th, 2016 \\AD.JEFCO.COM\BANKING\HEALTHCARE INTL\DEALS\NOR45600IB - TARGET\2. FROM COMPANY\011216
More informationDEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS
DEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS JEFFERIES GLOBAL HEALTHCARE CONFERENCE JUNE 8, 2017 LUIGI COSTA, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com
More informationDEVELOPING PRECISION THERAPIES IN HAEMATOLOGIC CANCERS
DEVELOPING PRECISION THERAPIES IN HAEMATOLOGIC CANCERS DNB HEALTHCARE CONFERENCE DECEMBER 14 TH, 2017 LUIGI COSTA, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com
More informationPARADIGME UPDATE APRIL Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway IR contact:
PARADIGME UPDATE APRIL 2018 Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: ir@nordicnanovector.com Key messages Revised timelines for PARADIGME data read-out
More informationTrubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007
Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007 Peter Thompson, M.D., FACP President, CEO and Chairman Trubion Pharmaceuticals, Inc. Safe Harbor
More informationASH 2017 BETALUTIN LYMRIT STUDY UPDATE
ASH 2017 BETALUTIN LYMRIT 37-01 STUDY UPDATE DECEMBER 11 TH, 2017 Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: tkvale@nordicnanovector.com Disclaimer
More informationAffimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH
FOR IMMEDIATE RELEASE Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated;
More informationDEVELOPING PRECISION THERAPIES IN HAEMATOLOGIC CANCERS
DEVELOPING PRECISION THERAPIES IN HAEMATOLOGIC CANCERS CHINA HEALTHCARE INVESTMENT & PARTNERING SYMPOSIUM (CHIPS) MARCH 15-17 TH, 2018 LUIGI COSTA, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo,
More informationBench-to-Bedside Translation of ADCs using PK/PD M&S. Dhaval K. Shah, Ph.D.
Bench-to-Bedside Translation of ADCs using PK/PD M&S Dhaval K. Shah, Ph.D. dshah4@buffalo.edu 8/23/2016 Outline Overview: ADCs Prediction of Clinical Efficacy using a Multi-Scale Mechanistic PK/PD Model
More informationDEVELOPING PRECISION THERAPIES IN HAEMATOLOGIC CANCERS
DEVELOPING PRECISION THERAPIES IN HAEMATOLOGIC CANCERS Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: tkvale@nordicnanovector.com Disclaimer This presentation
More informationICH S9 guideline on nonclinical evaluation for anticancer pharmaceuticals - questions and answers
16 May 2018 EMA/CHMP/ICH/453684/2016 Committee for Human Medicinal Products ICH S9 guideline on nonclinical evaluation for anticancer pharmaceuticals - questions and answers Step 5 Transmission to CHMP
More informationImmunodiscovery developing antibodies for research, diagnosis and therapy MATS OHLIN
Immunodiscovery developing antibodies for research, diagnosis and therapy MATS OHLIN Immunotechnology a department at Lund University exploiting advanced technologies in biomedicine Genomics Antibody technology
More informationDeveloping first-in-class treatments in Haematology Jefferies Healthcare Conference, London, 16 November Luigi Costa, Chief Executive Officer
Developing first-in-class treatments in Haematology Jefferies Healthcare Conference, London, 16 November 2016 Luigi Costa, Chief Executive Officer Forward-looking statements This presentation may contain
More informationInvestor Update. Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting
Investor Update Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting Ten medicines featured in over 70 abstracts, including
More informationS9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers
S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers Current Step 4 version International Council for Harmonisation of Technical
More informationQ1 18 HIGHLIGHTS AND FINANCIALS
Q1 18 HIGHLIGHTS AND FINANCIALS MAY 30 TH, 2018 TONE KVÅLE, CFO & INTERIM CEO LISA ROJKJAER, CMO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: IR@nordicnanovector.com
More informationImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update
August 2, 2013 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update Kadcyla sales off to strong start. Decision
More informationRACING TOWARD A CURE FOR BLOOD CANCERS WITH NEW CARS (CAR-T CELL THERAPY)
RACING TOWARD A CURE FOR BLOOD CANCERS WITH NEW CARS (CAR-T CELL THERAPY) Larry D. Anderson, Jr, MD, PhD Internal Medicine Grand Rounds University of Texas Southwestern Medical Center March 9, 2018 This
More informationAddressing challenges of targeting the macrophage checkpoint, CD47. Marie Kosco-Vilbois, PhD CSO
Addressing challenges of targeting the macrophage checkpoint, CD47 Marie Kosco-Vilbois, PhD CSO 1 CD47 is an immune checkpoint Cancer cell Macrophage Activating eat me signal CD47 Inhibitory don t eat
More informationAntibody therapeutic approaches for cancer
Antibody therapeutic approaches for cancer Date2innovate Utrecht, March 21, 2014 Jan van de Winkel Forward Looking Statement This presentation contains forward looking statements. The words believe, expect,
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/68231 holds various files of this Leiden University dissertation. Author: Engelberts, P.J. Title: CD20 as target for immunotherapy Issue Date: 2019-01-10
More informationChanging Lives. Daniel Junius, President and CEO June 3, Nasdaq: IMGN
Changing Lives Daniel Junius, President and CEO June 3, 215 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These
More informationMedia Release. Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
Media Release Basel, 01 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III
More informationANTIBODY THERAPY ANTIBODY THERAPY ANTIBODY THERAPY PDF MONOCLONAL ANTIBODY THERAPY - WIKIPEDIA ANTIBODY - WIKIPEDIA 1 / 5
PDF MONOCLONAL - WIKIPEDIA ANTIBODY - WIKIPEDIA 1 / 5 2 / 5 3 / 5 antibody therapy pdf Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mab) to bind monospecifically
More informationGenmab an antibody innovation powerhouse. Jan van de Winkel
Genmab an antibody innovation powerhouse Jan van de Winkel Forward Looking Statement This presentation contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar
More informationUPDATED IN HEMATOLOGIC MALIGNANCIES
UPDATED IN HEMATOLOGIC MALIGNANCIES EKAPUN KAROOPONGSE MD DIVISION OF HEMATOLOGY, MEDICINE MAHIDOL UNIVERSITY TREATMENT IN HEMATOLOGIC MALIGNANCIES Chemotherapy Immunotherapy Monoclonal antibody therapies
More informationImmune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 1, 2017 Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 01,
More informationComparability Studies for Autologous Cell Therapy Products. Chris Shen July, 2017
Comparability Studies for Autologous Cell Therapy Products Chris Shen July, 2017 Forward Looking Statements/Safe Harbor To the extent statements contained in this presentation are not descriptions of historical
More informationCD19 ADCs Effectively Targeting B Cell Malignancies a clinical perspective.
CD19 ADCs Effectively Targeting B Cell Malignancies a clinical perspective. Martin J.S. Dyer Helen and Ernest Scott Haematological Research Institute University of Leicester Dyer Financial Disclosures
More informationMonoclonal Antibodies
Monoclonal Antibodies Homogeneous antibody preparations produced in the laboratory by hybridomas. Produced by identical type of B cell clones. Recognize a signal epitope on an antigen. Hybridoma Technology
More informationMuctarr Sesay, Ph.D. Vice President of Process Development Goodwin Biotechnology Inc. (GBI), Plantation, Fl
Development, Manufacture and Preclinical evaluation and efficacy studies of a melanin IgM antibody labeled with Rhenium-188-Labeled against experimental human metastatic melanoma in nude mice Muctarr Sesay,
More informationOverview of the Antibody Drug Conjugate Landscape Godfrey Amphlett WCBP CMC Strategy Forum January 24, 2010
Overview of the Antibody Drug Conjugate Landscape Godfrey Amphlett WCBP CMC Strategy Forum January 24, 2010 Outline of Talk What is an Antibody Drug Conjugate (ADC)? Rationale for developing ADC s What
More informationBIMM18 Dec 20 th - Flow cytometry in clinical diagnostics
BIMM18 Dec 20 th - Flow cytometry in clinical diagnostics I. B cell leukemia and lymphomas Immunophenotyping as part of the diagnostic work- up of hematologic malignancies offers a rapid and effective
More informationNew Treatment Facility and Targeted Alpha-particle Therapy in FMU
New Treatment Facility and Targeted Alpha-particle Therapy in FMU Noboru Oriuchi, MD, PhD Advanced Clinical Research Center Fukushima Global Medical Science Center Fukushima Medical University FMU-ICRP
More informationS9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers
S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers Current version dated 8 June 2016 International Council for Harmonisation of
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationProduction of 177 Lu n.c.a. in high-flux reactors
Production of 177 Lu n.c.a. in high-flux reactors R. Henkelmann, S. Marx, K. Zhernosekov, M. Harfensteller February 2013 Outline Targeted Radionuclide Therapy Therapeutic Radionuclides c.a. vs n.c.a. Lutetium
More informationRXi Pharmaceuticals. BioPharm America September 26, 2017 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals BioPharm America September 26, 2017 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationscr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL OUTLOOK ZACKS ESTIMATES
Small-Cap Research April 28, 2016 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 MabVax Therapeutics Holdings, Inc. (MBVX - OTC) MBVX:
More informationCAR T-CELL THERAPIES WEBINAR. Scientific and Policy perspectives. 5 December :00-17:30 CET
CAR T-CELL THERAPIES Scientific and Policy perspectives WEBINAR 5 December 2017 16:00-17:30 CET Viviana Galli Coordinator, European Alliance for Responsible R&D and Affordable Medicines Tuna Mutis, MD,
More informationClinical-Stage Pipeline Today
Our Targeted Antibody Payload (TAP) technology uses tumor-targeting antibodies to deliver one of our potent cancer-cell killing agents specifically to tumor cells. Multiple TAP compounds are in clinical
More informationCorporate Presentation. April 2016
Corporate Presentation April 2016 1 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationTranslational development of Therapeutic Lymphoma Vaccines
Translational development of Therapeutic Lymphoma Vaccines Larry W. Kwak, M.D., Ph.D. Chairman, Department of Lymphoma/Myeloma Justin Distinguished Chair in Leukemia Research Assoc. Director, Center for
More informationAdoptive cellular therapies are based on the administration of live cells into a patient in order for them to serve a therapeutic purpose.
Adoptive cellular therapies are based on the administration of live cells into a patient in order for them to serve a therapeutic purpose. Pharmaceutical products have been historically made of purified
More informationCompany Update. February 2017
Company Update February 2017 Safe Harbor Forward looking statements This communication contains certain forward-looking statements, relating to the Company s business, which can be identified by the use
More informationBiologics Market: Where Are We Now? Where Are We Going?
Biologics Market: Where Are We Now? Where Are We Going? Rakesh Dixit, Ph.D., DABT Vice President, Research & Development AstraZeneca-Medimmune Biologics R & D Scope of Biologics Medicines Biotechnology
More informationComparative Oncology Program
The Problem: Non-Integrated Cancer Drug Development A Solution: Integration of Informative Non-Clinical Models of Cancer With Clinical Drug Development Efforts Companion Animal Malignancies as Comparative
More informationImmunity for Life TM. Sven Rohmann VP Business Development
Immunity for Life TM Sven Rohmann VP Business Development Disclaimer This Presentation includes and is based, inter alia, on forward-looking information and statements that are subject to risks and uncertainties
More informationMarina Biotech Monetizes UNA Intellectual Property Estate through Agreement with Arcturus Therapeutics
Marina Biotech Monetizes UNA Intellectual Property Estate through Agreement with Arcturus Therapeutics CAMBRIDGE, MA, August 14, 2013 Marina Biotech, Inc. (OTC Pink: MRNA): Assigns Unlocked Nucleobase
More informationMaking cancer a chronic disease. Troels Jordansen
Making cancer a chronic disease Troels Jordansen Glycostem corporate summary Clinical stage company developing allogeneic cellular products for cancer immunotherapy using NK-cells Founded in 2007 Until
More informationAMGEN AT ASH 2017: DEVELOPING LEADERSHIP IN BISPECIFIC THERAPIES DECEMBER 9, 2017
AMGEN AT ASH 2017: DEVELOPING LEADERSHIP IN BISPECIFIC THERAPIES DECEMBER 9, 2017 SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based on management s current expectations
More informationInvestor Update. Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
Investor Update Basel, 1 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III
More informationAdvancing Manufacturing for Advanced Therapies
Advancing Manufacturing for Advanced Therapies Peter Marks, MD, PhD Center For Biologics Evaluation and Research, FDA CASSS Cell & Gene Therapy Symposium July 10, 2018 Overview Cell and gene therapy products
More informationLinker p. 177 Helper Lipid p. 178 Delivery to Target Cells p. 180 Cell Entry p. 182 Receptor-Mediated Uptake p. 182 Endosomai Release p.
Overview of Regulatory Expectations for Introducing Novel Therapies into Clinical Trials Introduction p. 1 Roles of Regulatory Scientists p. 2 Product Development and Availability p. 2 Data Requirements
More informationCOMPARABILITY OF NOVEL THERAPEUTICS: CASE STUDIES FOR A BISPECIFIC T-CELL ENGAGER AND ONCOLYTIC VIRUS. FRANK MAGGIO, Ph.D. PRODUCT QUALITY PRINCIPAL
COMPARABILITY OF NOVEL THERAPEUTICS: CASE STUDIES FOR A BISPECIFIC T-CELL ENGAGER AND ONCOLYTIC VIRUS FRANK MAGGIO, Ph.D. PRODUCT QUALITY PRINCIPAL BLINATUMOMAB MECHANISM OF ACTION Apoptotic Cell Death
More information2111: ALL Post-HCT. Add/ Remove/ Modify. Manual Section. Date. Description. Comprehensive Disease- Specific Manuals
2111: ALL Post-HCT The Acute Lymphoblastic Leukemia Post-HCT Data Form is one of the Comprehensive Report Forms. This form captures ALL-specific post-hct data such as: planned treatments post-hct, the
More informationVenture Philanthropy Models: The Leukemia & Lymphoma Society's Therapy Acceleration Program. A FasterCures Webinar June 19, 2013
Venture Philanthropy Models: The Leukemia & Lymphoma Society's Therapy Acceleration Program A FasterCures Webinar June 19, 2013 What is FasterCures? Founded in 2003, our mission is to save lives by saving
More informationSupplementary Methods Antibodies for flow cytometry Cytotoxicity assay
Supplementary Methods Antibodies for flow cytometry HLA-Cw3 and CD2 expression: LCL 72.22 cell lines were stained with anti-hla-abc-apc (clone G46-2.6, BD) or migg-apc (clone MOPC-2, BD) antibody, or with
More informationAffimed: Developing First-In-Class Immune Cell Engagers for the Activation of Innate and Adaptive Immunity to Fight Cancer
Affimed: Developing First-In-Class Immune Cell Engagers for the Activation of Innate and Adaptive Immunity to Fight Cancer Corporate Presentation August, 2018 Forward-looking statements / safe harbor This
More informationJefferies Healthcare Conference. June 2016
Jefferies Healthcare Conference June 2016 Forward Looking Statements This presentation contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation
More informationPHASE 1, MULTICENTER, OPEN-LABEL STUDY OF SINGLE-AGENT BISPECIFIC ANTIBODY T CELL ENGAGER GBR 1342 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF SINGLE-AGENT BISPECIFIC ANTIBODY T CELL ENGAGER GBR 1342 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA JOSHUA RICHTER 1 ; OLA LANDGREN 2 ; JOHN KAUH 3 ; JONATHAN BACK
More informationZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities
August 9, 2016 ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities Company to Host Conference Call at 4:30 PM ET Today BOSTON, Aug. 09, 2016 (GLOBE NEWSWIRE)
More informationABOUT GLYCOSTEM. Company Overview
ABOUT GLYCOSTEM The company is a clinical stage biotech company established in the Netherlands in 2007. The company s headquarters and new state-of-the-art lab and production facilities are based at Pivot
More informationUNUM THERAPEUTICS CORPORATE PRESENTATION APRIL 2019
UNUM THERAPEUTICS CORPORATE PRESENTATION APRIL 2019 FORWARD-LOOKING STATEMENTS AND RISK FACTORS This presentation and the accompanying oral commentary contain forward-looking statements that involve risks,
More informationAntibody Targeted Amanitin Conjugates (ATACs) Expanding the ADC Landscape With a New Payload Targeting RNA Polymerase II
Antibody Targeted Amanitin Conjugates (ATACs) Expanding the ADC Landscape With a New Payload Targeting RNA Polymerase II ADC Summit 2016 San Diego Andreas Pahl CS Heidelberg Pharma GmbH Ladenburg, Germany
More informationPrecigen Company Update
Precigen Company Update Helen Sabzevari, PhD President, Precigen 9 January 2019 JP Morgan 37 th Annual Healthcare Conference Forward-looking statements Precigen, Inc. is a subsidiary of Intrexon Corporation
More informationDr. Nazareth Gengozian (Photo courtesy of Oak Ridge Associated Universities)
At age 77, Dr. Gengozian retired. He expressed his decision this way, I had been very fortunate to have had a professional career which I loved very much: The freedom to pursue basic research with only
More informationCreating Highly Efficacious ADCs for Low-Expression Targets While Improving Therapeutic Index TIM LOWINGER, PHD
Creating Highly Efficacious ADCs for Low-Expression Targets While Improving Therapeutic Index TIM LOWINGER, PHD CSO Mersana Therapeutics VC-backed Biotech in Cambridge, MA Investors: NEA, Pfizer, Fidelity,
More informationDeborah Dunsire, M.D. President and CEO. Annual Meeting of Shareholders Cambridge, MA May 4, 2006
Deborah Dunsire, M.D. President and CEO Annual Meeting of Shareholders Cambridge, MA May 4, 2006 2006 Millennium 2006 Pharmaceuticals Millennium Inc. Pharmaceuticals, Inc. Agenda 2005 Key Accomplishments
More informationFDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer
FDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer Yongjie Zhou, M.D., Ph.D. FDA/CBER/OCTGT/DCEPT Yongjie.zhou@fda.hhs.gov isbtc Global Regulatory Summit October 29, 2008
More informationImmunotherapy in Hemato-Oncology
ESMO Preceptorship Programme Immuno-Oncology From tumor immunology to clinical application 2-3 November 2016 Zurich - CH Immunotherapy in Hemato-Oncology Markus G. Manz Klinikdirektor Hämatologie USZ Leiter
More informationChallenges in Capturing Long Term Follow up of Recipients of Genetically Modified Cells. Cell Therapy Liaison Meeting January, 2018
Challenges in Capturing Long Term Follow up of Recipients of Genetically Modified Cells Cell Therapy Liaison Meeting January, 2018 Outline Development of the Cellular Therapy Registry Standardized Data
More informationBEH.462/3.962J Molecular Principles of Biomaterials Spring 2003
Lecture 17: Drug targeting Last time: Today: Intracellular drug delivery Drug targeting Reading: T.J. Wickham, Ligand-directed targeting of genes to the site of disease, Nat. Med. 9(1) 135-139 (2003) Drug
More informationGlobal Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box.
Global Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box. The purpose of this presentation Looking for Joint Venture
More informationPHASE 1, MULTICENTER, OPEN-LABEL STUDY OF SINGLE-AGENT BISPECIFIC ANTIBODY T CELL ENGAGER GBR 1342 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF SINGLE-AGENT BISPECIFIC ANTIBODY T CELL ENGAGER GBR 1342 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA JOSHUA RICHTER 1 ; MARTIN WERMKE 2 ; JOHN KAUH 3 ; JONATHAN BACK
More informationBiosimilar Monoclonal Antibodies: Registration Requirements. Henry M. J. Leng
Biosimilar Monoclonal Antibodies: Registration Requirements Henry M. J. Leng Disclaimer This presentation is given in my personal capacity and represents only the author s personal views and does not represent
More informationDevelopment of next generation DC-based cancer vaccines (DCVAC)
Development of next generation DC-based cancer vaccines (DCVAC) Jiří Heřmánek, CEO Russia 8 November 2013 Connecting patients and science 1. Company Introduction July 2013 2 SOTIO SOTIO is an international
More informationCAR-T Cells enter center stage!
CAR-T Cells enter center stage! COSTEM, Berlin, October 2017 Molmed sponsored symposium»approaches to potentially overcome CAR-T cell toxicity: anticytokine antibodies and suicide genes" Christian CHABANNION
More informationGenitope Corporation. Summary of MyVax Personalized Immunotherapy Phase 3 Clinical Trial Results
Genitope Corporation Summary of MyVax Personalized Immunotherapy Phase 3 Clinical Trial Results Introduction In December 27, Genitope Corporation ( Genitope ) obtained data indicating that its pivotal
More informationOncology Product and Platform Partnering Opportunity
Protein Medicinal Chemistry with an Expanded Genetic Code Oncology Product and Platform Partnering Opportunity April 2017 Ambrx has Made Advances in Proprietary Platform and Titer while Achieving Clinical
More informationEmerging treatments in Multiple myeloma. Josh Veatch Damian Green
Emerging treatments in Multiple myeloma Josh Veatch Damian Green Emerging treatments in multiple myeloma Introduction Daratumumab Elotuzumab PD 1 inhibitors HDAC inhibitors Other emerging therapies in
More informationJefferies Healthcare Conference
0 Jefferies Healthcare Conference 3 June 2015 NASDAQ: CRIS Forward Looking & Other Important Cautionary Statements This presentation contains forward-looking statements for purposes of the safe harbor
More informationNSE Grantees Meeting December 2015
NSE Grantees Meeting December 2015 The Spherical Nucleic Acid (SNA) Nanoparticle Changes the Paradigm for Oligo Therapeutics Linear DNA SNA Each company limited by chemistry, modality, and tissue of interest
More informationAffimed: Developing First-In-Class Immune Cell Engagers for Harnessing Innate and Adaptive Immunity to Fight Cancer
Affimed: Developing First-In-Class Immune Cell Engagers for Harnessing Innate and Adaptive Immunity to Fight Cancer Corporate Presentation September, 2018 Forward-looking statements / safe harbor This
More informationAffimed: Developing First-In-Class Immune Cell Engagers for Harnessing Innate and Adaptive Immunity to Fight Cancer
Affimed: Developing First-In-Class Immune Cell Engagers for Harnessing Innate and Adaptive Immunity to Fight Cancer Corporate Presentation October, 2018 Forward-looking statements / safe harbor This presentation
More informationQuantitative And Spatial Optimization Of Therapeutic Fusion Proteins
Quantitative And Spatial Optimization Of Therapeutic Fusion Proteins Jeffrey Way, Ph.D. Senior Staff Scientist, Wyss Institute, HMS CEO, General Biologics, Inc. 1 Chimeric Activators Drug design and targeted
More informationHELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY
HELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY PROVIDING COMPREHENSIVE SOLUTIONS IN A COMPLEX ENVIRONMENT PPD IS A PARTNER WITH PROVEN CAPABILITIES THAT SUPPORT AND ADVANCE ONCOLOGY RESEARCH
More informationBiotech Showcase 2016
1 Biotech Showcase 2016 Our Value Proposition Advancing broad product pipeline of biosimilars and next generation antibody therapeutics Proven track record in superior quality, efficient R&D and manufacturing
More informationSCM Lifescience COMPANY PROFILE BUSINESS AREAS. [Address] 310, 366 Seohae-daero, Jung-gu, Incheon, Korea [Website]
SCM Lifescience [Address] 310, 366 Seohae-daero, Jung-gu, Incheon, Korea 22332 [Website] http://www.scmlifescience.com COMPANY PROFILE [Industry] SCM Lifescience is a research-based biopharmaceutical company
More informationOral NT-KO-003 for the Treatment of Multiple Sclerosis
Oral for the Treatment of Multiple Sclerosis Madrid, 27 de noviembre de 2013 Content 1. The Company 2. The Product a) Target Indications b) Innovative mechanisms of action c) Differential features facing
More informationFDA Perspective on the Preclinical Development of Cancer Vaccines
FDA Perspective on the Preclinical Development of Cancer Vaccines Richard D. McFarland Ph.D., M.D. Medical Officer CBER/OCTGT/DCEPT mcfarlandr@cber.fda.gov Cancer Vaccine Clinical Trials Workshop Alexandria,
More informationTHIS OPINION IS CITABLE AS PRECEDENT OF THE TTAB UNITED STATES PATENT AND TRADEMARK OFFICE. Trademark Trial and Appeal Board
THIS OPINION IS CITABLE AS PRECEDENT OF THE TTAB Mailed: June 23, 2006 UNITED STATES PATENT AND TRADEMARK OFFICE Trademark Trial and Appeal Board In re Viventia Biotech Inc. Serial No. 76424575 William
More informationTHE ibritumomab tiuxetan regimen requires
Logistics of Radioimmunotherapy With Yttrium 90 Ibritumomab Tiuxetan (Zevalin) A. Michael Zimmer Radioimmunotherapy is a promising new therapeutic option for the treatment of B-cell non-hodgkin s lymphoma.
More informationAstellas to Acquire Agensys, Inc.
November 27, 2007 to Acquire, Inc. Japan, November 27, 2007 - Pharma Inc. ( ; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that its US subsidiary, US Holding, Inc. (headquarters:
More informationUNLEASH THE POWER OF PRECISION MEDICINE
FROM BENCH TO BEDSIDE UNLEASH THE POWER OF PRECISION MEDICINE DCB, pioneer in biotech. Your partner in drug discovery. www.dcb.org.tw The Center for Biotechnology With over 400 dedicated researchers and
More informationGSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma
GSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma 12 December 2017 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking
More information6 th EBF Open meeting, Barcelona November 21st, 2013
Validation of an immunoassay to selectively quantify the naked antibody of a new Sanofi Antibody Drug Conjugate: an additional tool for improvement of PK interpretation 6 th EBF Open meeting, Barcelona
More information